Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral LBH589 in chronic phase CML resistant to ≥2 TKIs
2006-000881-35Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoints: Major cytogenetic response rate and Duration of major cytogenetic response. Started Dec 2006; status: completed.
02
Drugs
panobinostat
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2006-000881-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000881-35.